<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307292</url>
  </required_header>
  <id_info>
    <org_study_id>QualiMed</org_study_id>
    <nct_id>NCT02307292</nct_id>
  </id_info>
  <brief_title>Prospective, Post Market Surveillance Q3-registry (POLARIS)</brief_title>
  <acronym>Q3-Registry</acronym>
  <official_title>Prospective, Non-randomized Post Market Surveillance Registry to Document the Clinical Performance in Routine Clinical Practice of the POLARIS Peripheral Vascular Self Expanding Stent System.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QualiMed Innovative Medizinprodukte GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QualiMed Innovative Medizinprodukte GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized post market surveillance registry designed to document
      the clinical Performance in Routine clinical practice of the POLARIS Peripheral Vascular Self
      Expanding Stent System
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Freedom from target lesion revascularization</measure>
    <time_frame>at 12 months</time_frame>
    <description>Clinically driven</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis/ reocclusion</measure>
    <time_frame>at 12 months</time_frame>
    <description>Defined as peak systolic velocity tatio (PSVR) &gt; 2.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target limb amputation at the index leg (major and minor separately)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in resting ankle brachial index (ABI)</measure>
    <time_frame>From baseline to 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford Classification</measure>
    <time_frame>From baseline to 12 and 24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>POLARIS Peripheral Vascular Self Expanding Stent System</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with single significant (&gt;50%) superficial femoral artery disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Single target de novo superficial femoral artery lesion (angiographic evidence of &gt;50%
             Stenosis or occlusion) by visual estimate

          -  Rutherford category II-IV

          -  At least one patent outflow artery to the ankle.

          -  Patient signed the informed consent

        Exclusion Criteria:

          -  Patient with acute or subacute Thrombus

          -  Patients with hyperkoagulopathy

          -  Patients with Stenosis or occlusion where lesion crossing with guide wire is not
             possible

          -  Pregnancy or positive pregnancy test

          -  Previous enrolment in this Trial or other industrial Trials

          -  PatientÂ´s inability to fully cooperate with the registry protocol Patient with cancer
             Treatment (life expectancy less than 2 years) Patients with renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Krankenberg, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Center Bad Bevensen, Department of Angiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sigrid Krimmer-Quendler, PhD</last_name>
    <phone>+40417165780</phone>
    <email>quendler@qualimed.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>HGZ Bad Bevensen, Department of Angiology</name>
      <address>
        <city>Bad Bevensen</city>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Krankenberg, MD, PhD</last_name>
      <phone>+495821821157</phone>
      <email>h.krankenberg@hgz-bb.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>January 9, 2015</last_update_submitted>
  <last_update_submitted_qc>January 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herz- und Gefaesszentrum Bad Bevensen</investigator_affiliation>
    <investigator_full_name>Hans Krankenberg</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Superficial femoral artery</keyword>
  <keyword>Self Expanding Stent System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

